Find out the latest updates from Trevi Therapeutics (NASDAQ:TRVI) as they make significant progress in their clinical development programs. Learn about the latest trials and what to expect in the coming months.
Trevi Therapeutics has reached a major milestone in its Phase 2b CORAL trial, targeting chronic cough in idiopathic pulmonary fibrosis patients. With 50% of enrollment completed, the trial is set for a sample size re-estimation in December 2024. Topline results are expected in the first half of 2025.
Additionally, the company has finished dosing in its Human Abuse Potential study, with results due in December 2024. The Phase 2a RIVER trial for refractory chronic cough has reached its planned sample size, with topline results expected in Q1 2025.
Despite these positive developments, it's important to note that forward-looking statements are subject to risks and uncertainties. Factors like trial success and regulatory opinions could impact actual results.
Analysis and Implications
Trevi Therapeutics' progress in clinical trials is promising, but financial challenges persist. While the company's stock has faced recent declines, its balance sheet shows a favorable cash position compared to debt. This financial stability could support ongoing trials.
Investors should consider the extended timelines for trial results and the company's focus on clinical development. As Trevi Therapeutics continues to advance its trials, including the CORAL and RIVER trials, market reactions and financial performance will be key indicators to watch.
For a more detailed analysis, check out InvestingPro's additional tips on Trevi Therapeutics to gain deeper insights into the company's financial health and market position.